Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer S(+)ibuprofen fever study data needed; FDA committee votes against approval.

This article was originally published in The Tan Sheet

Executive Summary

BAYER S(+)IBUPROFEN FEVER REDUCTION STUDY NEEDED, FDA's Nonprescription Drugs and Arthritis Drugs Advisory Committees concluded at an Oct. 9 joint meeting in Bethesda, Md. The committees voted 9-1 not to recommend Bayer's S(+)ibuprofen (dexibuprofen) 200 mg caplets for approval as an OTC analgesic (NDA 20-373). Bayer's proposed indications are the temporary relief of minor aches and pains associated with the common cold, headache, toothache, muscle aches, back ache, menstrual cramps, minor pain of arthritis and temporary reduction of fever ("The Tan Sheet" Sept. 9, p. 3).
Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel